SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Bicara Therapeutics Inc. (BCAX) News

Follow Bicara Therapeutics Inc. (BCAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol BCAX Asset equity Sector Markets 90 days 5 Last 8.46 Updated Nov 09, 2026, 12:53 PM UTC Open live news feed Open BCAX chart & news
M Bicara Reports Q3 2026 Net Loss of $71.2 Million Bicara reported a net loss of $71.2 million for the third quarter of 2026, versus $36.3 million a year earlier. It had $442.3 million in cash, cash equivalents and marketable securities at September 30, 2026, and expects EQUITY | Nov 09, 2026, 12:53 PM UTC M Bicara Therapeutics Q3 Net Loss Widens on Higher R&D Costs EQUITY | Nov 09, 2026, 12:42 PM UTC M Bicara Therapeutics to Report Third-Quarter Results on November 9 Bicara Therapeutics says it will report third-quarter 2026 financial results and business updates on November 9, 2026, at 8:30 a.m. ET. EQUITY | Nov 02, 2026, 01:30 PM UTC L Bicara Therapeutics awards inducement grants under Nasdaq Rule 5635(c)(4) Bicara Therapeutics said it awarded inducement grants on Sept. 1, 2026 to two new employees under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 03, 2026, 12:37 PM UTC L BCAX - Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BCAX - Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) EQUITY | Sep 03, 2026, 12:30 PM UTC M BCAX reiterates Market Outperform, sets $31 price target Hammerstone MarketTalk says BCAX reiterates Market Outperform and assigns a $31 price target after a Q2 update at Citizens. EQUITY | Aug 21, 2026, 11:08 AM UTC L BCAX upgraded to Outperform with $35 price target at BMO BCAX is rated Outperform and given a $35 price target by BMO, according to Hammerstone MarketTalk. EQUITY | Aug 19, 2026, 11:48 AM UTC L BMO, Wedbush, Wolfe and RBC issue stock initiations BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK. EQUITY | Aug 19, 2026, 11:09 AM UTC L Bicara Therapeutics announces Nasdaq Rule 5635(c)(4) inducement grant Bicara Therapeutics (BCAX) announces an inducement grant under Nasdaq Listing Rule 5635(c)(4), as stated in the provided release text. REGULATION | Aug 14, 2026, 12:30 PM UTC L BCAX - Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET - Click Fo BCAX - Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET EARNINGS | Aug 04, 2026, 12:30 PM UTC L Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing () -- Ryan Cohlhepp, Director, President and COO, on July 08, 2026, sold 28,750 shares in Bicara Therapeutics (BCAX) for $833,129. Following the Form 4 filing with the SEC, Cohlhepp has control over a total of 181,641 co GEOPOLITICS | Jul 10, 2026, 08:20 PM UTC